drugset
drugset / Trial / NCT07358806

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

NCT07358806 ↗

Phase 1 Recruiting 51 enrolled Oscotec Inc.
RandomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.

Timeline

Start
2025-12-18
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject OCT-598 Unknown 100 mg Oral
Subject OCT-598 Unknown 200 mg Oral
Subject OCT-598 Unknown 300 mg Oral
Subject OCT-598 Unknown 500 mg Oral
Subject OCT-598 Unknown 800 mg Oral
Subject OCT-598 Unknown 1200 mg Oral
Background Docetaxel Small molecule — —

Indications

breast cancer gastroesophageal cancer head and neck cancer non-small cell lung carcinoma prostate cancer